Navigation Links
Bradmer announces 2008 first quarter operational and financial results
Date:5/9/2008

TSX: BMR

TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 first quarter operational and financial results.

Operational Highlights

During the three months ended March 31, 2008, the Company achieved the following steps in preparation for the upcoming multi-center Phase III trial and subsequent planned commercialization for its lead drug Neuradiab, a treatment for glioblastoma multiforme, the most deadly form of brain cancer:

- Prepared and submitted the Company's drug manufacturing data package

to the FDA. The submission is currently under review. After

completion of the review and satisfactory resolution of any further

requests of the FDA, if any, Bradmer will submit a clinical update to

its Investigational New Drug (IND) application and proceed with the

launch of the planned Phase III trial.

- Entered formal contracting and approval processes with more than 30

U.S. clinical trial sites, in line with previously stated site

recruitment goals.

- Appointed Robert Tessarolo, Vice-President Sales & Marketing, Biovail

Pharmaceuticals Canada to the Board of Directors

- Hired Jukka Karjalainen, M.D., Ph.D. as Chief Operating and Medical

Officer.

"We have made significant progress toward the start of our planned multi-center Phase III trial of Neuradiab in patients with glioblastoma. Our submission to the FDA focuses specifically on reducing risk in the critical areas of manufacturing, regulatory and clinical operations," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We have successfully completed all aspects of workup required to start this trial and await the review of the FDA. We look forward to enrolling
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Bradmer announces new additions to management team
2. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
3. Notice of Bradmer Pharmaceuticals Conference Call
4. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
5. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
6. Bradmer announces additions to Scientific Advisory Board
7. Bradmer Medical Isotope Supply For Phase III Trial Secure
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer provides Phase III Neuradiab trial update and guidance
10. Bradmer announces management changes
11. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Florida (PRWEB) , ... August 28, 2015 , ... ... holistic approach to medicine through health promotion and disease prevention, improving a patient’s ... most prevalent diseases in the community, including heart disease, cancer, diabetes, HIV/AIDS, STDs, ...
(Date:8/27/2015)... Atlanta, Georgia (PRWEB) , ... August 28, 2015 ... ... a positive impact on elementary school students’ academic performance in mathematics, according to ... in the journal Education, Finance and Policy in July, analyzed the impact of ...
(Date:8/27/2015)... BWI (PRWEB) , ... August 28, 2015 , ... Grace ... This award is added to an already impressive list of accolades for the ... was ranked as the #2 beach in the world by TripAdvisor, the world's leading ...
(Date:8/27/2015)... California (PRWEB) , ... August 27, 2015 , ... Keck ... , Seventy-seven students received their White Coats at a formal ceremony recognizing them as ... of the pharmacy profession on Saturday, August 22. Symbolizing dedication to clinical service and ...
(Date:8/27/2015)... ... ... Mesa Community College graduate, Andrew Sypher (Mesa), is one of ... leadership and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, to ... and a $7,500 scholarship to assist in his goal of becoming a foreign diplomat ...
Breaking Medicine News(10 mins):Health News:Health Clinic Opening and Public Art Unveiling 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 2Health News:Four-Day School Week Can Improve Academic Performance, Study Finds 3Health News:Grace Bay Beach Acknowledged as a Top Caribbean Beach for Weddings 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3
... The American Academy of Family Physicians today announced the ... first alliance partner, The Coca-Cola Company. , (Logo: ... is a program that allows corporate partners like The ... consumers about the role their products can play in ...
... are not addressing the main differences between neighborhood food ... or reduce obesity, according to a new RAND Corporation study. ... Angeles region has no more fast-food chain establishments on a ... rather many more small food stores and other food outlets. ...
... The founders of HEAL Africa ( www.hea ... nonprofit organization that provides holistic healing including urgent care medical services ... of Congo, are conducting a seven-city tour of the U.S. to ... of war in Congo. HEAL Africa,s approach to healing conflict has ...
... ,Symphony of the Superhero, to Feature DJ Cut Chemist, Violinist ... Boychoir, Whittier Elementary Choir, The Raretones and Bells of the ... The Symphony Guild today announced ... the Superhero, an annual event which benefits Seattle ...
... in some, but effects were fleeting, scientists say , MONDAY, ... addicts beat their habit is showing some effect but is ... one-third of participants in a new study developed desired immune ... cocaine use did go down. But the effects were only ...
... ... competitive advantage , ... (PRWEB) October 5, 2009-- BodyMedia, Inc. , the pioneer in developing wearable body monitoring ... Ki Performance. Through the company,s first strategic partner in Europe, BodyMedia is extending its ...
Cached Medicine News:Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 2Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 3Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 4Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 2Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 3Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 2Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 3Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 2Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 2Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 3
(Date:8/28/2015)... The scientific team of a new biotech company ... academics in the field of aging Prof. Robert J. ... for model animals - 10 fold for nematodes) has recently ... primarily, around the stability and stress resistance of certain gene ... analysis of a model gene network links aging, stress resistance, ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today announced ... Logo - ... "Our new corporate identity signifies our transformation into a ... predictive analytics platform for patent claim validity." ... of the proprietary AIA Shield™ platform, the Company commenced a ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
Breaking Medicine Technology:Gero: Physics Meets Biology to Help Defeat Aging 2Gero: Physics Meets Biology to Help Defeat Aging 3IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... with no dose-limiting toxicities - - ... Halozyme to seek input from regulatory authorities in order to ... into pivotal clinical program ... Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company developing and,commercializing ...
... the identification of,the gene responsible for progeria, a ... of Spanish and French researchers (Carlos,Lopez-Otin and coll. ... and coll. -,Inserm/AP-HM, Marseille, France) have successfully demonstrated ... combining two existing,pharmacological molecules, should slow down the ...
Cached Medicine Technology:Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 2Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 3Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 4Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial 5Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The ACMI™ line of laparoscopic hand instruments is designed to provide a wide selection of popular surgical devices to meet procedural needs....
Medicine Products: